Why the study?
Adjuvant breast radiotherapy following breast-conserving surgery can induce cardiac toxicity, prompting investigation into the incidence and risk factors of major coronary events.
What are the incidence and risk factors for major coronary events in breast cancer patients receiving adjuvant breast radiotherapy after breast-conserving surgery?
What are the incidence and risk factors for major coronary events in breast cancer patients receiving adjuvant breast radiotherapy after breast-conserving surgery?
Major coronary events occur in approximately 5.3% of breast cancer patients within 3 years of adjuvant radiotherapy, with traditional cardiovascular risk factors and specific cancer therapies increasing the risk.
Purpose: Adjuvant breast radiotherapy (RT) following breast-conserving surgery (BCS) has been reported to induce cardiac toxicity in breast cancer patients. We investigated the incidence and risk factors of major coronary events after breast RT using Korean nationwide Health Insurance Review and Assessment data. Methods: Using data from a nationwide quality assessment of breast cancer treatment, we identified 3,251 patients who received breast RT after BCS in 2013. Data about major coronary events were additionally collected from national claims data. We defined major coronary events according to the International Classification of Diseases, 10th revision (ICD-10) codes I20-25. Results: A total of 172 major coronary events (5.3%) occurred among 3,251 breast cancer patients. The 1-year, 2-year, and 3-year coronary event-free survival rates were 98.1%, 96.4% and 95.2%, respectively. Patients with underlying diabetes mellitus (88.6% vs. 95.7%, p < 0.001), high blood pressure (HBP) (89.4% vs. 96.3%, p < 0.001), and cerebrovascular accident (CVA) (84.0% vs. 95.4%, p < 0.001) showed significantly worse 3-year coronary event-free survival rates than those without comorbidities. Multivariate analysis revealed that patient age (p < 0.001), HBP (p < 0.001), CVA (p = 0.025), adjuvant hormonal therapy (p = 0.034), and Herceptin therapy (p < 0.001) were significantly associated with major coronary events in breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Sung et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: